Female Genitourinary Diseases and Pregnancy Complications
Female urogenital disorders and pregnancy complications are important issues that affect women's health. These diseases include, but are not limited to, urinary tract infections, vaginitis, endometriosis, uterine fibroids, gestational diabetes, and gestational hypertension.
- Among female urogenital disorders, urinary tract infections and vaginitis are more common, and these disorders are usually caused by bacteria, fungi, or viruses. The main medications used to treat these conditions include antibiotics, antifungals, and antivirals. In addition, estrogen replacement therapy is used to treat genitourinary symptoms associated with menopause.
- Complications of pregnancy include gestational diabetes mellitus, gestational hypertension, and preeclampsia, which pose significant risks to the health of the pregnant woman and the fetus. Drug development for the treatment of pregnancy complications has focused on controlling blood glucose and blood pressure and improving fetal growth.
Female Genitourinary Diseases and Pregnancy Complications Drug Targets
Female Genitourinary Diseases and Pregnancy Complications Related Signaling Pathway
Female Genitourinary Diseases and Pregnancy Complications Drug Target Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
Human GH1 protein his/myc tag (CSB-MP009407HU) captured on COOH chip can bind Human GHR protein Fc tag (CSB-MP009411HU) with an affinity constant of 6.1 nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized Human IL2RA at 2μg/mL can bind Anti-IL2RA recombinant antibody (CSB-RA011649MA1HU)，the EC50 is 2.463-3.353 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized MSLN at 2 μg/ml can bind Anti-MSLN rabbit monoclonal antibody, the EC50 of the MSLN protein is 2.657-3.177 ng/ml.
